Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

PF-06835919

Generic Name: PF-06835919

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

Phase 1

Completed

Posted: 2020/06/11

Sponsor:Pfizer

ID:NCT04427917

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Phase 2

Completed

Posted: 2019/05/31

Sponsor:Pfizer

ID:NCT03969719

THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS

Phase 1

Completed

Posted: 2019/04/16

Sponsor:Pfizer

ID:NCT03916406

Multiple Ascending Dose and DDI Study

Phase 1

Completed

Posted: 2017/01/25

Sponsor:Pfizer

ID:NCT03031119

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Phase 1

Completed

Posted: 2016/11/28

Sponsor:Pfizer

ID:NCT02974374

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies

6 months ago

The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy